Heptares and Allergan sign $3.35 billion deal in neuro diseases

7 April 2016
heptares-big

Hot on the heels of its abandoned $160 billion mega-merger with US pharma giant Pfizer, Ireland-domiciled Allergan (NYSE; AGN) has announced a major collaboration with Heptares Therapeutics, that could earn the latter as much as $3.35 billion, reinforcing chief executive Brent Saunders confidence as a standalone company (The Pharma Letter April 6).

UK-based Heptares, a wholly-owned subsidiary of Japan’s Sosei group (TYO: 4565) has entered into a definitive agreement under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.

Shares in Sosei, which acquired Heptares last year for as much as $400 million, rose more than 21% to 17,180 yen on news of the deal today (TPL February 23, 2015).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical